Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)

NCT02798406 is registered in ClinicalTrials.gov with DNAtrix, Inc. as lead sponsor.

NCT NCT02798406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02798406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Lead sponsor
DNAtrix, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 6, 2016
Completion date
June 30, 2021
Enrollment
49 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, brain neoplasm, glioblastoma, glioma, gliosarcoma, malignant brain tumor, neoplasm by histologic type, neoplasm, nerve tissue, neoplasm, neuroepithelial, nervous system diseases, neuroectodermal tumors